×

BRIEF-Boehringer Ingelheim, Eli Lilly give data from a pooled analysis of two mid-stage trials in adults with type 2 diabetes

Oct 2 (Reuters) - Eli Lilly and Co :

* Clinical data for investigational SGLT2 inhibitor, empagliflozin,

demonstrates potential for oral treatment in type 2 diabetes

* Says empagliflozin was well-tolerated

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))